Government-Owned Inventions; Availability for Licensing, 50668 [2018-21767]
Download as PDF
<![CDATA[
50668
Federal Register / Vol. 83, No. 195 / Tuesday, October 9, 2018 / Notices
neutralizing antibody.’’ Science
352.6287 (2016): 828–833.
(b) Xu, Kai, et al. ‘‘Epitope-based
vaccine design yields fusion
peptide-directed antibodies that
neutralize diverse strains of HIV–
1.’’ Nature Medicine 24, 857–867
(2018).
Intellectual Property: HHS Reference
Number E–279–2016 includes U.S.
Provisional Patent Application Number
62/403,266 filed 10/03/2016 and PCT
Application Number PCT/US2017/
054959 filed 10/03/2017 (pending).
Licensing Contact: Barry Buchbinder,
Ph.D., 240–627–3678;
barry.buchbinder@nih.gov
Dated: September 25, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2018–21762 Filed 10–5–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
amozie on DSK3GDR082PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
Peter Soukas, J.D., 301–594–8730;
peter.soukas@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
VerDate Sep<11>2014
19:13 Oct 05, 2018
Jkt 247001
Recombinant RSV B1 Expressing eGFP
as a Reporter Gene
Description of Technology: The
inventors have created a reverse
genetics system for RSV strain B1 of
antigenic subgroup B encoding a
replication-competent recombinant RSV
that contains a codon-optimized G ORF
and expresses enhanced green
fluorescence protein (GFP). There are
two antigenic subgroups of RSV,
subgroups A and B, and most of the
available information and reagents are
for subgroup A. Immunity against either
subgroup has reduced effectiveness in
restricting the heterologous subgroup,
suggesting that an effective RSV vaccine
might need to contain both subgroups.
The sequence of the wild type G gene
was refractory to cloning into full-length
antigenomic cDNA in E. coli, and so the
inventors made and successfully used a
codon optimized version. In addition,
the inventors inserted an eGFP gene into
the first gene position (promoter
proximal). The resulting virus is
replication-competent and efficiently
expresses GFP in infected cells. This
virus can be used as a tool to detect
RSV-neutralizing antibodies to RSV
subgroup B in a plaque-reduction assay.
It also can be used to evaluate RSV
infection in vitro and in vivo using GFP
fluorescence to track infection. The
antigenomic cDNA clone also provides
the starting material for making liveattenuated subgroup B-specific RSV
vaccine candidates containing defined
mutations. These defined mutations can
include ones that we previously
developed for RSV subgroup A, and
include stabilized point mutations,
stabilized codon-deletions, and genedeletions.
The present invention provides a
reverse genetics system encoding strain
B1 of RSV subgroup B containing a
codon-optimized G ORF and encoding
eGFP. This provides a tool for RSV
subgroup B serology assays, for tracking
RSV infection, and a starting point for
making attenuated subgroup B strains
for vaccine purposes.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Viral diagnostics
• Vaccine research
• Serology assays
• Vaccine manufacture
Competitive Advantages:
• Ease of manufacture
• Unique research tool
Development Stage:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
• In vitro data assessment
Inventors: Ursula Buchholz (NIAID),
Peter Collins (NIAID).
Publications: None.
Intellectual Property: HHS Reference
No. E–159–2018–0.
Licensing Contact: Peter Soukas, J.D.,
301–594–8730; peter.soukas@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize for development of a
vaccine for respiratory or other
infections. For collaboration
opportunities, please contact Peter
Soukas, J.D., 301–594–8730;
peter.soukas@nih.gov.
Dated: September 25, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2018–21767 Filed 10–5–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Generic Clearance
To Conduct Voluntary Customer/
Partner Surveys (NLM)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
SUMMARY:
Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, should be
directed to the: Office of Management
and Budget, Office of Regulatory Affairs,
OIRA_submission@omb.eop.gov or by
fax to 202–395–6974, Attention: Desk
Officer for NIH.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
ADDRESSES:
E:\FR\FM\09OCN1.SGM
09OCN1
]]>Agencies
[Federal Register Volume 83, Number 195 (Tuesday, October 9, 2018)]
[Notices]
[Page 50668]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-21767]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Soukas, J.D., 301-594-8730;
[email protected]. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Recombinant RSV B1 Expressing eGFP as a Reporter Gene
Description of Technology: The inventors have created a reverse
genetics system for RSV strain B1 of antigenic subgroup B encoding a
replication-competent recombinant RSV that contains a codon-optimized G
ORF and expresses enhanced green fluorescence protein (GFP). There are
two antigenic subgroups of RSV, subgroups A and B, and most of the
available information and reagents are for subgroup A. Immunity against
either subgroup has reduced effectiveness in restricting the
heterologous subgroup, suggesting that an effective RSV vaccine might
need to contain both subgroups. The sequence of the wild type G gene
was refractory to cloning into full-length antigenomic cDNA in E. coli,
and so the inventors made and successfully used a codon optimized
version. In addition, the inventors inserted an eGFP gene into the
first gene position (promoter proximal). The resulting virus is
replication-competent and efficiently expresses GFP in infected cells.
This virus can be used as a tool to detect RSV-neutralizing antibodies
to RSV subgroup B in a plaque-reduction assay. It also can be used to
evaluate RSV infection in vitro and in vivo using GFP fluorescence to
track infection. The antigenomic cDNA clone also provides the starting
material for making live-attenuated subgroup B-specific RSV vaccine
candidates containing defined mutations. These defined mutations can
include ones that we previously developed for RSV subgroup A, and
include stabilized point mutations, stabilized codon-deletions, and
gene-deletions.
The present invention provides a reverse genetics system encoding
strain B1 of RSV subgroup B containing a codon-optimized G ORF and
encoding eGFP. This provides a tool for RSV subgroup B serology assays,
for tracking RSV infection, and a starting point for making attenuated
subgroup B strains for vaccine purposes.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Viral diagnostics
Vaccine research
Serology assays
Vaccine manufacture
Competitive Advantages:
Ease of manufacture
Unique research tool
Development Stage:
In vitro data assessment
Inventors: Ursula Buchholz (NIAID), Peter Collins (NIAID).
Publications: None.
Intellectual Property: HHS Reference No. E-159-2018-0.
Licensing Contact: Peter Soukas, J.D., 301-594-8730;
[email protected].
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize for development of a vaccine for
respiratory or other infections. For collaboration opportunities,
please contact Peter Soukas, J.D., 301-594-8730; [email protected].
Dated: September 25, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-21767 Filed 10-5-18; 8:45 am]
BILLING CODE 4140-01-P
